Skip to main content
Premium Trial:

Request an Annual Quote

Connecticut Reference Lab to Sell Genomas Dx System for Drug Metabolism

NEW YORK, Oct. 26 (GenomeWeb News) - Genomas launched its HILOmet PhysioType System and announced a distribution agreement with Newington, Conn.-based Clinical Laboratory Partners, the company said today.

 

Similar to Roche Diagnostic's AmpliChip CYP450 test, based on Affymetrix's Gene Chip technology that was approved late last year, the HILOmet System uses DNA-based typing of 3 cytochrome p450 genes, CYP 2C9, 2C19, and 2D6 to determine individual rates of drug metabolism.

 

The company's Laboratory of Personalized Health will perform the HILOmet tests.

 

"Blood samples will be drawn by our phlebotomists at our many facilities throughout Connecticut and sent to the LPH," George M. Kyriacou, president of Clinical Laboratory Partners, said in a statement. LPH and CLP will provide DNA typing reports to the physicians.

 

Gulaberto Ruaño, a former vice chairman and chief scientific officer of Genaissance, launched Genomas in 2003 to study individual genetic responses to stress, exercise, climate, and disease.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.